Opening book details…
Can I read Cardiovascular Disease and Metabolic Dysfunction-associated Steatotic Liver Disease: Pathophysiology and Diagnostic Aspects on EtoBox?
Cardiovascular Disease and Metabolic Dysfunction-associated Steatotic Liver Disease: Pathophysiology and Diagnostic Aspects by Søren Møller & Nina Kimer & Jens Dahlgaard Hove & Mads Barløse & Lise Lotte Gluud is a book available to read on EtoBox.
What is Cardiovascular Disease and Metabolic Dysfunction-associated Steatotic Liver Disease: Pathophysiology and Diagnostic Aspects about?
DOI: 10.1093/eurjpc/zwae306; European Journal of Preventive Cardiology, 2025-03-03.; Abstract: Metabolic dysfunction-associated steatotic liver disease (MASLD) can be interpreted as the hepatic expression of metabolic syndrome, which is estimated to affect 30% of the adult population. Obesity, dyslipidaemia, arterial hypertension, and T2DM are considered significant risk factors of MASLD. The relationship is two-way with MASLD found in up to 75% of patients with T2DM. Importantly, MASLD is associated with increased risk of cardiovascular diseases (CVD) such as arrhythmia, atherosclerotic heart disease, heart failure, and CVD-associated mortality. In addition, MASLD patients present with a high prevalence of major adverse cardiac events, which calls for systematic surveillance of CVD in MASLD. This review focuses on the pathophysiology behind development of CVD in MASLD, the types of cardiovascular complications, morbidity and survival, and suggestions for evaluation of patients with MASLD.
- Author
- Søren Møller & Nina Kimer & Jens Dahlgaard Hove & Mads Barløse & Lise Lotte Gluud
- Publisher
- x
- Published
- 2025
- Language
- EN
More by Søren Møller & Nina Kimer & Jens Dahlgaard Hove & Mads Barløse & Lise Lotte Gluud
Similar books
- The Bidirectional Immune Crosstalk in Metabolic Dysfunction-associated Steatotic Liver Disease — Keisuke Sawada & Hak Chung & Samir Softic & Maria E. Moreno-Fernandez & Senad Divanovic (2023)
- Hepatic TM6SF2 Activates Antitumour Immunity to Suppress Metabolic Dysfunction-associated Steatotic Liver Disease-related Hepatocellular Carcinoma and Boosts Immunotherapy — Yating Zhang (2025)
- Nutritional and Metabolic Bases of Cardiovascular Disease — Mario Mancini; Jose M. Ordovas; Gabrielle Riccardi; Paolo Rubba; Pasquale Strazzullo (2011)
- Metabolic Risk for Cardiovascular Disease — Robert H Eckel; American Heart Association (2011)
- EASL–EASD–EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): Executive Summary (2024)
- Metabolic Syndrome and Psychiatric Illness : Interactions, Pathophysiology, Assessment and Treatment — Scott D. Mendelson; Charles B. Nemeroff (2008)